Description

Simple

Clinical

Overview

A barbiturate that is effective as a hypnotic and sedative.

Pharmacology

Indication

For the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.

Pharmacodynamic

Hexobarbital is a barbiturate derivative having hypnotic and sedative effects. It was subsequently used in the 1940s and 1950s as an anesthetic for surgery. Furthermore, the agent also demonstrates a fairly quick onset of action that also possesses a short duration of action. However it can be diffi... Read more

Mechanism of action

Hexobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

Absorption

Information currently not available.

Protein binding

25%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Hexobarbital
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The metabolism of (R)-warfarin can be decreased when combined with Hexobarbital.
(S)-Warfarin
The metabolism of (S)-Warfarin can be decreased when combined with Hexobarbital.
1,10-Phenanthroline
The therapeutic efficacy of Hexobarbital can be decreased when used in combination with 1,10-Phenanthroline.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Hexobarbital is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthine
The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be decreased when it is combined with Hexobarbital.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when Hexobarbital is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarin
The metabolism of 4-hydroxycoumarin can be increased when combined with Hexobarbital.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when Hexobarbital is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Hexobarbital is combined with 5-methoxy-N,N-dimethyltryptamine.
6-O-benzylguanine
The serum concentration of 6-O-benzylguanine can be decreased when it is combined with Hexobarbital.
7-Deazaguanine
The serum concentration of 7-Deazaguanine can be decreased when it is combined with Hexobarbital.
7-Nitroindazole
The risk or severity of adverse effects can be increased when Hexobarbital is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Hexobarbital is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
7,9-Dimethylguanine
The serum concentration of 7,9-Dimethylguanine can be decreased when it is combined with Hexobarbital.
8-azaguanine
The serum concentration of 8-azaguanine can be decreased when it is combined with Hexobarbital.
8-chlorotheophylline
The serum concentration of 8-chlorotheophylline can be decreased when it is combined with Hexobarbital.
9-Deazaguanine
The serum concentration of 9-Deazaguanine can be decreased when it is combined with Hexobarbital.
9-Methylguanine
The serum concentration of 9-Methylguanine can be decreased when it is combined with Hexobarbital.
Abatacept
The metabolism of Hexobarbital can be increased when combined with Abatacept.
Abiraterone
The metabolism of Hexobarbital can be decreased when combined with Abiraterone.
4 References
  1. 1 . Takenoshita R, Toki S: [New aspects of hexobarbital metabolism: stereoselective metabolism, new metabolic pathway via GSH conjugation, and 3-hydroxyhexobarbital dehydrogenases]. Yakugaku Zasshi. 2004 Dec;124(12):857-71.PubMed: 15577260
  2. 2 . Wahlstrom G: A study of the duration of acute tolerance induced with hexobarbital in male rats. Pharmacol Biochem Behav. 1998 Apr;59(4):945-8.PubMed: 9586853
  3. 3 . Korkmaz S, Ljungblad E, Wahlstrom G: Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat. Brain Res. 1995 Apr 10;676(2):371-7.PubMed: 7614008
  4. 4 . Dall V, Orntoft U, Schmidt A, Nordholm L: Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital. Pharmacol Biochem Behav. 1993 Sep;46(1):73-6.PubMed: 8255925